Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAY121 single-ascending-dose phase 1 study in healthy volunteers
NL-OMON60656Phase 1Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Dec 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial comparing RAY121 with Placebo (2 arms). Primary endpoint: Safety and tolerability. Started Dec 2024; status: completed.
02
Drugs
RAY121
Beyond the preview
Go deeper on NL-OMON60656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60656.